Form 4: Exagen Inc. CEO John Aballi Acquires 40,401 Shares of Common Stock
SEC Form 4 Filing
Exagen Inc.'s President and CEO, John Aballi, recently purchased 40,401 shares of the company's common stock at a price of $1.92 per share.
Summary
- On May 16, 2024, John Aballi, the President and CEO of Exagen Inc., acquired 40,401 shares of common stock.
- The purchase price was $1.92 per share.
- Following the transaction, Aballi directly owns 600,788 shares and indirectly owns 40,401 shares through his spouse.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is generally viewed as a positive sign, indicating confidence in the company's future.
Positives
- The CEO's purchase of shares may signal confidence in the company's future prospects.
Industry Context
Insider transactions are closely monitored as they can provide insights into a company's performance and future prospects. CEO's buying shares is generally seen as a positive sign.
Stakeholder Impact
- Shareholders may view the CEO's stock purchase as a positive signal.
Key Dates
| Date | Description |
|---|---|
| 05/16/2024 | Date of the stock transaction. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.